Friday, 5 Sep 2025
  • About Us
  • Contact Us
  • Terms and Conditions
  • Privacy Policy
Subscribe
Life Care News
  • Home
  • Business
    • Business Wire
    • Globenews Wire
  • News
    NewsShow More
    ADFW 2025: World’s Financial Elite Managing Over USD 60 Trillion to Explore How Technology is Shaping Finance
    ADFW 2025: World’s Financial Elite Managing Over USD 60 Trillion to Explore How Technology is Shaping Finance
    05/09/2025
    Starburst Announces AI & Datanova 2025, the Global Virtual Summit for Trino, Data and AI Innovation
    Starburst Announces AI & Datanova 2025, the Global Virtual Summit for Trino, Data and AI Innovation
    05/09/2025
    James Hardie Releases Annual Sustainability Report
    James Hardie Releases Annual Sustainability Report
    04/09/2025
    StudyIn Announces Completion of its Transaction with SUN Education
    StudyIn Announces Completion of its Transaction with SUN Education
    04/09/2025
    Coventry and Alan Buerger Move to Dismiss Abacus Lawsuit
    Coventry and Alan Buerger Move to Dismiss Abacus Lawsuit
    03/09/2025
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
  • 🔥
  • news
  • june
  • global
  • Business
  • july
  • today
  • announced
  • aug
  • company
  • Tech
Font ResizerAa
Life Care NewsLife Care News
  • Home
  • Business
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Search
  • Home
  • Business
    • Business Wire
    • Globenews Wire
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Follow US
© 2022 Foxiz News Network. Ruby Design Company. All Rights Reserved.
Tech

Novotech Earns Frost & Sullivan’s 2025 Global Company of the Year Recognition for Excellence in Biotech Clinical Research Services

PRNW Agency
Last updated: 03/07/2025 12:20 PM
PRNW Agency
Share
7 Min Read
Novotech Earns Frost & Sullivan’s 2025 Global Company of the Year Recognition for Excellence in Biotech Clinical Research Services
SHARE
Novotech Earns Frost & Sullivan’s 2025 Global Company of the Year Recognition for Excellence in Biotech Clinical Research Services

Recognized for its biotech-first focus, innovation in clinical trial delivery, and best-in-class client experience, Novotech sets the global standard in contract research for biotechs and small- mid-size pharma companies.

- Advertisement -

SAN ANTONIO, July 3, 2025 /PRNewswire/ — Frost & Sullivan is pleased to announce that Novotech has been awarded the 2025 Global Company of the Year Award in the biotech contract research organization (CRO) industry for its outstanding achievements in clinical trial innovation, strategic execution, and client-centric delivery. This recognition highlights Novotech’s leadership in enabling biotech and small to mid-sized pharma companies to accelerate therapeutic development globally through flexible, high-touch, and technologically advanced clinical trial services.

- Advertisement -

The company stands apart in the global CRO landscape with its strategic emphasis on serving biotech clients, offering tailored clinical trial solutions across all phases of development. The company operates in more than 30 locations and has cultivated deep local insights across key clinical trial hubs, including Australia, South Korea, India, China, and the United States. Its ability to combine global standards with regional excellence makes Novotech a trusted partner for biotech sponsors worldwide.

“Novotech is redefining biotech-focused clinical research through AI-driven innovation, global expansion, and a client-embedded partnership model. With a clear vision to be the CRO of choice for biotech and small to midsize pharma, Novotech leverages deep therapeutic expertise and regional agility to deliver speed, flexibility, and transformative impact in clinical trials,” said Unmesh Lal, vice president, healthcare & life sciences at Frost & Sullivan.

- Advertisement -

With nearly three decades of experience, Novotech has built a robust reputation for delivering high-quality clinical trials at speed. Its integrated service model encompasses regulatory consulting, clinical operations, biometrics, data management, and medical writing, allowing clients to streamline their development pipelines from early phase to post-marketing studies. Through a powerful combination of local knowledge, scientific expertise, and digital capabilities, Novotech continues to enhance trial efficiency, patient recruitment, and regulatory outcomes.

- Advertisement -

Novotech’s dedication to advancing clinical research is further reflected in its strategic acquisitions and partnerships. The company’s expansions into the United States and Europe marked a significant milestone in building a globally unified platform while preserving its excellence in APAC operations. Novotech’s sustained growth trajectory is driven by its deep alignment with sponsors’ evolving needs and its commitment to scientific excellence and operational agility.

“We’re honored by Frost & Sullivan’s recognition, which highlights Novotech’s strategic focus on delivering regional expertise through a global model to support biotech and mid-size pharma sponsors. It also reflects the strength of our teams in driving operational, scientific, and client delivery excellence worldwide,” said Dr. John Moller, chief executive officer, Novotech

- Advertisement -

Novotech’s unwavering commitment to client experience strengthens its position in the market. By streamlining service delivery, enabling real-time trial visibility through advanced digital systems, and maintaining continuity across project teams, the company delivers exceptional client satisfaction. Its regionalized, partner-led delivery model and localized expertise ensure regulatory compliance and cultural alignment—key factors that drive trial success in various markets.

- Advertisement -

Frost & Sullivan commends Novotech for setting a high standard in competitive strategy, execution, and market responsiveness. The company’s vision, innovation pipeline, and client-first culture are shaping the future of biotech clinical trials and driving tangible outcomes that matter to patients and sponsors.

Each year, Frost & Sullivan presents the Company of the Year Award to a company that demonstrates outstanding strategy development and implementation, resulting in measurable improvements in market share, client satisfaction, and competitive positioning. The award recognizes forward-thinking organizations that are reshaping their industries through innovation and growth excellence.

- Advertisement -

Frost & Sullivan Best Practices awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, client service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.

- Advertisement -

About Frost & Sullivan

For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, megatrends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

- Advertisement -

Contact:
Tarini Singh
E: Tarini.Singh@frost.com

- Advertisement -

About Novotech
Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase.
With a global footprint that includes 30+ offices across the Asia-Pacific region, North America, and Europe and partnerships with 5,000+ trial sites, Novotech provides clients an accelerated path to bring life-changing therapies to market by providing access to key clinical trial destinations and diverse patient populations. 

Through its client-centric service model, Novotech seamlessly integrates people, processes, and technologies to deliver customized solutions that accelerate the path to market for life-changing therapies. By adopting a true partnership approach, Novotech shares a steadfast commitment to client success, empowering innovation, and advancing healthcare worldwide. Recipient of numerous industry accolades, including the Frost & Sullivan CRO Company of the Year award for 19 consecutive years, Novotech is recognized for its excellence in clinical trial execution and innovation. Its deep therapeutic and regulatory expertise, combined with local market insights, ensures streamlined clinical trials, optimized data analytics, and accelerated patient recruitment strategies. 

- Advertisement -

Together with clients, Novotech transforms scientific advancements into therapies that improve global health outcomes, embodying a mission of driving innovation and delivering impactful results.

- Advertisement -

For more information visit www.Novotech-CRO.com

Photo – https://mma.prnewswire.com/media/2723927/Frost_Sullivan_Novotech_Award.jpg 

- Advertisement -

 

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/novotech-earns-frost–sullivans-2025-global-company-of-the-year-recognition-for-excellence-in-biotech-clinical-research-services-302497234.html

Smilegate to Publish Absurd Ventures’ AAA Open-World Game Set in the A BETTER PARADISE Universe
PotisEdge Secures Fifth Consecutive BNEF Tier 1 Ranking in Q3 2025
YXT.com’s AI Learning Platform Deployed by Siemens for Digital Workforce Transformation
Nxera Pharma to Receive US$4.8 Million in Milestone Payments Following Centessas Initiation of Clinical Development of ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist
ELLKAY President & CEO Joins White House Health IT Summit to Help Push Interoperability Forward
TAGGED: for the2025acrossantoniobestinclassbiotechbiotechfirstbiotechsclientclinicalcompaniescompanycontractcrodeliverydevelopmentearnsexcellenceexperiencefocusfrostglobalInnovationjulymidsizenewsnovotechpharmarecognitionrecognizedResearchsanservicessetssmallstandardstrategicsullivan’strialyear
Share This Article
Facebook Copy Link Print
- Advertisement -

Your Trusted Source for Accurate and Timely Updates!

Our commitment to accuracy, impartiality, and delivering breaking news as it happens has earned us the trust of a vast audience. Stay ahead with real-time updates on the latest events, trends.
FacebookLike
XFollow
PinterestPin
InstagramFollow
YoutubeSubscribe
LinkedInFollow
MediumFollow

Most Selling Products

Top Picks, Trending Now – Discover the Best Sellers!
Tecno Camon 20 Premier 5G

Tecno Camon 20 Premier 5G

Dark Welkin | 8GB RAM + 512GB Storage (Expandable RAM up to 16GB) | Industry’s 1st 50MP RGBW-Pro Camera | Segment-First 108MP Ultra-Wide Macro Lens | 6.67" 120Hz 10-bit AMOLED In-Display

iQOO Z10 Lite 5G

iQOO Z10 Lite 5G

Titanium Blue | 6GB RAM + 128GB Storage | Dimensity 6300 5G with 433K+ AnTuTu Score | Robust 6000mAh Battery | IP64 Rated + Military-Grade Shock Resistance

OnePlus 13s

OnePlus 13s

Black Velvet | 12GB RAM + 256GB Storage | Flagship Snapdragon® 8 Elite Chipset | Exceptional Battery Life in a Compact Form | Lifetime Display Warranty Included

Samsung Galaxy A55 5G

Samsung Galaxy A55 5G

Awesome Iceblue | 8GB RAM + 256GB Storage | Premium Metal Frame | 50MP OIS Main Camera with Nightography | IP67 Water & Dust Resistance | Gorilla Glass Victus+ | sAMOLED Display with Vision Booster

You Might Also Like

Saudi Arabia leaps from 104th to 23rd globally in the Mining Investment Attractiveness Index
Entertainment

Saudi Arabia leaps from 104th to 23rd globally in the Mining Investment Attractiveness Index

15/08/2025
Mineralys Therapeutics Announces Pricing of Upsized 0.0 Million Underwritten Public Offering of Common Stock
Health

Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock

03/09/2025
Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
Health

Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

13/08/2025
Coventry and Alan Buerger Move to Dismiss Abacus Lawsuit
News

Indie Fashion Brand IshqMe Pays Tribute to Nature with its New Enchanting Garden Collection

03/07/2025
Life Care News
Facebook Twitter Youtube Rss Medium

Life Care News:


We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.

Top Categories
  • Home
  • Business
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Usefull Links
  • About Us
  • Contact Us
  • Terms and Conditions
  • Privacy Policy
Copyright © 2015 – 2025 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Life Care NewsLife Care News
Copyright © 2015 - 2025 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?